Scientific Findings Also Accepted and Published in American
Society for Microbiology Journal

WOBURN, Mass.--(BUSINESS WIRE)--Mar 18, 2010 - BioSense
Technologies, a pioneer in the development of diagnostic systems
for rapid drug susceptibility testing, announced today that it
presented key scientific findings at the National Foundation for
Infection Disease 2010 Annual Conference on Antimicrobial
Resistance, held in Bethesda, MD in early February. The Company
presented compelling scientific data in a poster presentation
(www.biosensetech.com/publications.htm)
demonstrating that its Z-Sense™ Differential Impedance
Sensing diagnostic system rapidly and accurately identified the
drug susceptibility of bacteria, yeast, and cancer cells exposed to
therapeutic agents in near real-time. The growing resistance of
bacteria to antibiotics combined with the shortage of available new
drugs threatens the ability to cure infections that were previously
treatable.

The Company's findings were also accepted and published in the
November 2009 issue of Antimicrobial Agents and
Chemotherapy. This journal article reported that the
Z-Sense™ system distinguished susceptible from resistant
strains of slow-growing tuberculosis bacteria exposed to
anti-tuberculosis drugs in less than one hour.

BioSense's Z-Sense™ Differential Impendence Sensing system
is a revolutionary new approach to rapid drug susceptibility
testing that monitors the physiological stress developed in cells
during exposure to pharmaceutical compounds to determine the effect
of a drug on the cells. The Company has found that monitoring the
dielectric permittivity of the test sample, an easily measured
electronic property, is a practical and accurate way to monitor the
development of stress. The cellular stress response occurs within
minutes enabling test results to be obtained immediately. Until
now, drug susceptibility testing required days or longer times
because these tests are based on cellular proliferation. Because
test results are currently not readily available, physicians often
prescribe costly drugs based on empirical evidence leading to
inappropriate treatments and poor patient outcomes. Inadequate or
delayed detection of drug resistance is a major contributor to the
prevalence of drug resistant strains of bacteria. In cancer
therapy, it can result in the prescription of ineffective drugs
while exposing patients to unnecessary toxic side effects.

“Our technology has the potential to dramatically improve
the treatment of life threatening diseases such as cancer and
antibiotic resistant bacterial infections” stated Dr. Ron
Rieder, President and Founder of BioSense Technologies. “Our
first generation Z-Sense diagnostic devices and test cartridges
have obtained drug susceptibility data that are now being validated
by independent institutions. The technology has proven itself to be
robust and results have been reproducible. We have reduced our
patented inventions to practice by developing a practical, easy to
use and cost-effective diagnostic testing system. This year we plan
to make further improvements to the Z-Sense Differential Impedance
Sensing system so that we can move the product into clinical
studies.”